炎症性肠病相关药物性胰腺炎的研究进展  

Progress in research of drug-induced pancreatitis associated with treatment of inflammatory bowel disease

作　　者：费诗茵 陈洁[2] 刘军[2] 王婷婷[1] 周盟 何家俊 Fei Shiyin;Chen Jie;Liu Jun;Wang Tingting;Zhou Meng;He Jiajun(Dalian Medical University,Dalian 116000,China;Department of Gastroenterology,Subei People's Hospital,Yangzhou 225000,China)

机构地区：[1]大连医科大学,辽宁大连116000 [2]苏北人民医院消化科,江苏扬州225000

出　　处：《中华临床医师杂志（电子版）》2021年第3期213-217,共5页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：炎症性肠病(IBD)是一种慢性、非特异性肠道炎症性疾病,常规治疗在使用药物快速诱导缓解后还往往需要相关药物的长期维持治疗。药物的安全性既是实现长期维持的关键,也是目前临床上终止用药的首要因素。在许多已知的IBD治疗药物的不良反应中药物性胰腺炎是一种较为严重的不良反应,常常导致停药而影响IBD患者的治疗。本文对治疗IBD的常用药物导致的药物性胰腺炎的研究进展、可能病理机制做了归纳总结,以提高临床医生的认识,加强临床监护。Inflammatory bowel disease(IBD)is a chronic,non-specific intestinal inflammatory disease.Conventional treatment often requires long-term maintenance treatment with related drugs after rapid induction of remission.The safety of drugs is not only the key to achieving long-term maintenance,but also the primary factor for clinical drug discontinuation.Among the known adverse reactions of drugs for the treatment of inflammatory bowel disease,drug-induced pancreatitis is a serious adverse reaction,which often leads to the withdrawal of drugs and affects the treatment of patients with inflammatory bowel disease.In this paper,we summarize the research progress and possible pathological mechanism of drug-induced pancreatitis caused by commonly used drugs for the treatment of inflammatory bowel disease,in order to raise clinician's awareness of the disease and strengthen clinical monitoring.

关 键 词：炎症性肠病 药物性胰腺炎 药物不良反应 

分 类 号：R576[医药卫生—消化系统] R574[医药卫生—内科学]